Treatment of acute infectious purpura fulminans with activated protein C.
Infectious purpura fulminans is associated with high mortality and morbidity despite standard antimicrobial therapy. We report satisfactory clinical outcome in two children with sepsis associated purpura fulminans who were treated with activated protein C (APC). There is need for proper evaluation of the efficacy of this extremely expensive therapeutic modality by randomized controlled trials before it is made standard of care in childhood infectious purpura fulminans.
Lokeshwar
M R
MR
Department of Pediatrics, P.D. Hinduja National Hospital and Research Center, Veer Savarkar Marg, Mumbai 400 016, India.
Singhal
T
T
Udani
S V
SV
Kapadia
F N
FN
D000208:Acute Disease; D000925:Anticoagulants / Q000627:therapeutic use*; D001779:Blood Coagulation Factors / Q000187:drug effects*; D002675:Child, Preschool; D006801:Humans; D011695:IgA Vasculitis / Q000188:drug therapy*; D007223:Infant; D008297:Male; D011486:Protein C / Q000627:therapeutic use*; D011956:Receptors, Cell Surface / Q000187:drug effects*; D016896:Treatment Outcome
D000925:Anticoagulants; D001779:Blood Coagulation Factors; D011486:Protein C; D011956:Receptors, Cell Surface; C091963:activated protein C receptor